Clinical Trial Update: Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder [Phase 2]

View source ↗

Summary

Phase 2 double-blind, placebo-controlled trial evaluating adding paliperidone to treatment-resistant obsessive-compulsive disorder. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• Paliperidone (Invega) (paliperidone)

Snippet

Sponsor: University of South Florida | Conditions: Obsessive-Compulsive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2014-02-06